Anti-Parvovirus type B19 Monoclonal antibody, Clone 632-6E

Background: Fibrin glue effectively controls air leakage in lung surgery; however, allogenic fibrin glue cannot eliminate the risks of infection and allergy despite current sterilization methods. Autologous fibrin glue (AFG) could be a good alternative, but is not commonly used worldwide because of its limited availability and lack of evidence. Herein, we report clinical outcomes of AFG in thoracic surgery. Methods: We retrospectively analyzed patients who underwent lobectomies or segmentectomies between November 2016 and September 2017 in our institution. We used two types of AFGs. One was a partially-autologous fibrin glue (PAFG), the components of which are largely autologous but which contains allogenic thrombin. The other was a completely-autologous fibrin glue (CAFG) which has no allogenic components. PAFG was used in the first half of the study period, after which CAFG was used from March 2017 onward. Patients who did not undergo AFG generation were categorized as the non-AFG group. The perioperative outcomes of the three groups were evaluated. Results: A total of 207 patients underwent lung surgery, including 118 lobectomies and 89 segmentectomies. Among them, 83 patients received PAM, 94 received CAFG, and 30 received non-AFG. The mean postoperative drainage period was within a few days in each group (PAFG vs. CAFG vs. nonAFG: 3.23=3.91 vs. 3.16=4.04 vs. 3.17 +/- 4.16 days, respectively; P=0.405), and the incidence of postoperative prolonged air leakage was within an acceptable range (PAFG vs. CAFG vs. non-AFG: 13.3% vs. 12.8% vs. 16.7%, respectively; P=0.821). Conclusions: The use of AFG is clinically feasible for patients who undergo lobectomies or segmentectomies. AFGs could be a viable alternative to conventional allogenic fibrin glues.

Parvovirus infection (PVI) is widespread in the world; more than 80% of the adult population have antibodies of IgG class to parvovirus B19. Malaria is a vector-borne parasitic disease caused by the protozoa of the genus Plasmodium, that is widespread in the countries of Africa, Southeast Asia, Oceania. The objective of the present study was to evaluate the effect of parvovirus B19 infection on the clinical course of malaria and the outcome of the underlying disease. During the period 2016-2018 blood plasma samples of 316 patients from the hospital of the Friya Prefecture of the Republic of Guinea (GR) with confirmed diagnosis of malaria were examined for the presence of PVB19 DNA. The clinical course of malaria in 316 examined patients was divided into group of either mild or complicated. In total, PVB19 DNA was detected in blood plasma in 55 of 316 patients (17.41 +/- 2.13%). But in the group with co-infection of PVB19 and P. falciparum complications were observed in 40 of 55 (72.73 +/- 2.75%) patients, and in 6 of 55 cases (10.91 +/- 4.40%) the disease resulted in death. In the group of patients with malaria without PVI, complications occurred in 99 of 261 patients (37.9 +/- 3.0%); of those 2 (0.77 +/- 0.54%) died. It was found that the most numerous group in the structure of malaria patients is represented by children under 5 (median 3) years (89, or 28.25 +/- 2.53%). Our results correlate with the data of other researchers who studied the PVI-associated malaria in children in malaria-endemic regions: among children under 5 years, the absolute majority of cases of PVI was accompanied by a complicated course of malaria. The primary parvovirus infection can aggravate the course of malaria, especially when combined with other unfavorable conditions (iron deficiency, malnutrition, helminthic infections, co-infections, etc.). Thus, infection with PVB19 becomes a critical factor, which can provoke a severe life-threatening anemia, and also cause other complications.